Continued process verification (Stage 3) rolled out

Continued process verification (CPV) is the third stage of the process-validation lifecycle. Stage 1 covers process design, Stage 2 covers process qualification including process performance qualification (PPQ), and Stage 3 confirms that a process remains in a validated state during routine commercial manufacture. Until now, batch data at Ergopharm were reviewed reliably but on a largely batch-by-batch and periodic basis. The Stage 3 rollout brings that monitoring under a single documented programme, applied consistently across the sterile injectable and oral-solid families produced at the Ergopharm Advanced Research Centre in Vadodara.

“By trending critical attributes across every batch, Ergopharm can see a process drifting before it reaches a specification limit — not after.”

In practice, each product family now has a defined set of critical quality attributes and critical process parameters that are trended across batches rather than assessed only against individual specification limits. Data drawn from batch manufacturing records, in-process controls and finished-product testing — fill weight and volume, assay, dissolution for oral solids, and sterility and endotoxin outcomes for injectables — are collated on a rolling basis and reviewed for shifts, drift and unexpected variability. Emerging signals feed the site's existing deviation, out-of-specification, out-of-trend and CAPA routes, and the accumulated trends inform the annual Product Quality Review for each family.

The programme is built on ICH Q10, which frames the pharmaceutical quality system around process performance and product-quality monitoring, CAPA, change management and management review. It also reflects the wider three-stage view of process validation, in which continued process verification is the ongoing assurance that follows successful process qualification. All trending is recorded under ALCOA+ data-integrity principles, and periodic review of the accumulated data is carried out under Qualified Person oversight as part of routine batch release decisions.

The practical benefit is earlier and more consistent detection of process variation. Because attributes are watched as trends rather than pass/fail points, a gradual shift can be investigated before it reaches a specification limit, supporting more stable capacity planning and fewer late-stage rejections. The consolidated dataset also strengthens change control — proposed changes can be assessed against a documented performance baseline — and improves traceability, since each family now carries a continuous, auditable record of how its validated process is behaving in commercial manufacture.